The delay of disease onset by Nec-1 in R6/2 transgenic mouse of HD further confirms the involvement of RIP1 signaling in disease pathogenesis and can be considered as a potential therapeutic approach to improve symptoms in HD patients [66]. Here, RIPK1 is linked to Huntington disease.